Terms: = Liver cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990
20 results:
1. The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers.
Yu A; Cao M; Zhang K; Yang Y; Ma L; Zhang X; Zhao Y; Ma X; Fan Z; Han Z; Wang H
Front Immunol; 2023; 14():1256355. PubMed ID: 37868990
[TBL] [Abstract] [Full Text] [Related]
2. Direct Conversion of Human Endothelial Cells Into liver cancer-Forming Cells Using Nonintegrative Episomal Vectors.
Goya T; Horisawa K; Udono M; Ohkawa Y; Ogawa Y; Sekiya S; Suzuki A
Hepatol Commun; 2022 Jul; 6(7):1725-1740. PubMed ID: 35220676
[TBL] [Abstract] [Full Text] [Related]
3. MSI-L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients.
Torshizi Esfahani A; Seyedna SY; Nazemalhosseini Mojarad E; Majd A; Asadzadeh Aghdaei H
J Cell Physiol; 2019 Aug; 234(8):13128-13136. PubMed ID: 30549036
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma.
Hu J; Wang N; Yang Y; Ma L; Han R; Zhang W; Yan C; Zheng Y; Wang X
BMC Gastroenterol; 2018 Dec; 18(1):186. PubMed ID: 30545306
[TBL] [Abstract] [Full Text] [Related]
5. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
[TBL] [Abstract] [Full Text] [Related]
7. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.
Wang K; Bai Y; Chen S; Huang J; Yuan J; Chen W; Yao P; Miao X; Wang Y; Liang Y; Zhang X; He M; Yang H; Guo H; Wei S
Cancer Med; 2018 Jun; 7(6):2691-2698. PubMed ID: 29696820
[TBL] [Abstract] [Full Text] [Related]
8. Hepatocellular Carcinoma in Noncirrhotic liver with Glycogenotic Foci: Basic Science Meets Genomic Medicine.
Lefkowitch JH; Lagana SM; Kato T
Semin Liver Dis; 2015 Nov; 35(4):450-6. PubMed ID: 26676821
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract] [Full Text] [Related]
10. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization.
Ray CE; Brown AC; Green TJ; Winston H; Curran C; Kreidler SM; Glueck DH; Rochon PJ
AJR Am J Roentgenol; 2015 Feb; 204(2):440-7. PubMed ID: 25615768
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
[TBL] [Abstract] [Full Text] [Related]
12. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.
Chang KC; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH; Yen MF; Lin SC; Yen YH; Tsai MC; Tseng PL; Hu TH
J Antimicrob Chemother; 2012 Nov; 67(11):2766-72. PubMed ID: 22899800
[TBL] [Abstract] [Full Text] [Related]
13. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract] [Full Text] [Related]
14. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region.
Sun M; Eshleman JR; Ferrell LD; Jacobs G; Sudilovsky EC; Tuthill R; Hussein MR; Sudilovsky O
Hepatology; 2001 Jun; 33(6):1415-24. PubMed ID: 11391530
[TBL] [Abstract] [Full Text] [Related]
15. L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers.
Hsieh LL; Huang RC; Yu MW; Chen CJ; Liaw YF
Cancer Lett; 1996 Jun; 103(2):171-6. PubMed ID: 8635154
[TBL] [Abstract] [Full Text] [Related]
16. Characteristics of human hepatocellular carcinoma cell lines (Hep-KANO) derived from a non-hepatitic, non-cirrhotic hepatitis B virus carrier.
Baba M; Hasegawa H; Nakayabu M; Tamaki S; Watanabe S; Shima T; Suzuki S; Kusano I; Kamada N
Jpn J Cancer Res; 1994 Nov; 85(11):1105-11. PubMed ID: 7829395
[TBL] [Abstract] [Full Text] [Related]
17. L-myc proto-oncogene alleles and susceptibility to hepatocellular carcinoma.
Taylor JA; Bell DA; Nagorney D
Int J Cancer; 1993 Jul; 54(6):927-30. PubMed ID: 8392982
[TBL] [Abstract] [Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
[TBL] [Abstract] [Full Text] [Related]
19. Heterogenous amplification of myc family oncogenes in small cell lung carcinoma.
Noguchi M; Hirohashi S; Hara F; Kojima A; Shimosato Y; Shinkai T; Tsuchiya R
Cancer; 1990 Nov; 66(10):2053-8. PubMed ID: 2171744
[TBL] [Abstract] [Full Text] [Related]
20. Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes.
Yokota J; Wada M; Yoshida T; Noguchi M; Terasaki T; Shimosato Y; Sugimura T; Terada M
Oncogene; 1988 Jun; 2(6):607-11. PubMed ID: 2838790
[TBL] [Abstract] [Full Text] [Related]
